Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety and Efficacy of RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer

NCT04338763 is registered in ClinicalTrials.gov with Rise Biopharmaceuticals, Inc. as lead sponsor.

NCT NCT04338763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04338763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety and Efficacy of RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer
Lead sponsor
Rise Biopharmaceuticals, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
April 19, 2021
Completion date
December 31, 2025
Enrollment
48 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pancreatic cancer metastatic, pancreatic cancer non-resectable